The Bioaccessibility Research Group of Europe (BARGE) has carried out an interlaboratory trial of a proposed harmonised in vitro physiologically based ingestion bioaccessibility procedure for soils, called the Unified BARGE Method (UBM). The UBM includes an initial saliva phase and simulated stomach and intestine compartments. The trial involved the participation of seven laboratories (five European and two North American) providing bioaccessibility data for As (11 samples), Cd (9 samples) and Pb (13 samples) using soils with in vivo relative bioavailability data measured using a swine model. The results of the study were compared with benchmark criteria for assessing the suitability of the UBM to provide data for human health risk assessments. Mine waste and slag soils containing high concentrations of As caused problems of poor repeatability and reproducibility which were alleviated when the samples were run at lower soil to solution ratios. The study showed that the UBM met the benchmark criteria for both the stomach and stomach & intestine phase for As. For Cd, three out of four criteria were met for the stomach phase but only one for the stomach & intestine phase. For Pb two, out of four criteria were met for the stomach phase and none for the stomach & intestine phase. However, the study recommends tighter control of pH in the stomach phase extraction to improve between-laboratory variability, more reproducible in vivo validation data and that a follow up inter-laboratory trial should be carried out.
Introduction
The Bioaccessibility Research Group of Europe (BARGE, http://www.bgs.ac.uk/barge/home.html) is a European network bringing together international institutes and research groups to study human bioaccessibility of priority contaminants in soils via the gastrointestinal (GI) tract. The key contaminants included in this work are arsenic (As), lead (Pb) and cadmium (Cd) as they are potentially harmful to human health (ATSDR, 2007b; ATSDR, 2007a; ATSDR, 2008) and the most common elements undergoing bioaccessibility research Ruby et al., 1993; Ruby et al., 1996; Albores et al., 2000; Oomen et al., 2002; Marschner et al., 2006; Chan et al., 2007; Datta et al., 2007; Drexler and Brattin, 2007; Finzgar et al., 2007; Hansen et al., 2007; Juhasz et al., 2007a Juhasz et al., , 2007b Ljung et al., 2007; Sarkar et al., 2007; Subacz et al., 2007; Turner and Ip, 2007; Van de Wiele et al., 2007; Beak et al., 2008; Moseley et al., 2008; Girouard and Zagury, 2009; Morman et al., 2009; Nagar et al., 2009; Poggio et al., 2009; Smith et al., 2009; Zhang et al., 2009; Demetriades et al., 2010; Juhasz et al.2010 ).
These contaminants are associated with a legacy of industrial activities (Gasser et al., 1996; Razo et al., 2006; Rieuwerts et al., 2006; Basta et al., 2007; Laird et al., 2007; Morrison and Gulson, 2007; Romero et al., 2008; Caboche et al.,2010; Meunier et al.,2010; and natural background geology (Fendorf et al., 2004; Koch et al., 2005; Nathanail et al., 2005; Palumbo-Roe et al., 2005; Wragg, 2005; Cave et al., 2007; Juhasz et al., 2007b; , which are of concern to a number of the countries participating in BARGE.
The accurate determination of bioaccessibility has the potential to make a significant impact on current risk assessment practice. BARGE has been involved in comparing and evaluating the physico-chemical processes within the many models and systems that have been developed over the years to measure bioaccessibility and contaminant exposure e.g. (Oomen et al., 2002; Basta et al., 2007; Cave et al., 2007; Chan et al., 2007; Gal et al., 2007; Gron et al., 2007; Ljung et al., 2007; Nathanail and Smith, 2007; Palumbo-Roe and Klinck, 2007; Subacz et al., 2007; Van de Wiele et al., 2007; Wragg and Klinck, 2007) . A priority objective is to provide robust and defensible data on bioaccessibility that can be used in human health risk assessments and policy making.
The concepts of bioaccessibility and oral bioavailability are fundamentally important for quantifying the risks that are associated with oral exposure to environmental contaminants. Bioaccessibility refers to the fraction of a contaminant that is released from soil into solution by digestive juices. It represents the maximum amount of contaminant that is available for intestinal absorption. In general, only a fraction of these bioaccessible contaminants can be absorbed by the intestinal epithelium. Inorganic contaminants are subsequently transported to the liver via the portal vein for biotransformation. The fraction of parent compound that reaches the systemic circulation is referred to as the bioavailable fraction. Given the fact that bioaccessibility is one of the principal factors limiting the bioavailable fraction, it is an important parameter to measure for risk assessment purposes.
Bioavailability data from actual human soil feeding tests is scarce (Maddaloni et al., 1998; Stanek et al.,2010) and although in vivo animal studies are have been carried out, these are, in general costly, time consuming, have ethical constraints and there is usually only a limited amount of soil available (Freeman et al., 1992; Freeman et al., 1993; Ruby et al., 1993; Freeman et al., 1995; Golub et al., 1999; Rodriguez et al., 1999; Ellickson et al., 2001; Schroder et al., 2003; Schroder et al., 2004; Marschner et al., 2006; Makris et al., 2008; Bannon et al., 2009; Nagar et al., 2009 ) and Juhasz et al (2007a Juhasz et al ( , 2008 Juhasz et al ( , 2009a Juhasz et al ( , 2009b ). An alternative is the application of in vitro models that simulate the GI tract.
These screening methods can be used to measure the bioaccessible contaminant fraction, as bioaccessibility is an important parameter prior to bioavailability. A number of in vitro bioaccessibility tests for mimicking human ingestion have been reported in the literature and have been comprehensively reviewed Dean and Ma, 2007) .
Of these, there are four batch extraction methods which are most commonly used : the physiologically based extraction test (PBET) originally developed by Ruby (1996) ; the in vitro gastrointestinal method (IVG) (Rodriguez et al., 1999) ; the Dutch National Institute for Public Health and the Environment method (RIVM) (Versantvoort et al., 2004) which is mainly used in Europe; and the relative bioaccessibility leaching procedure (RBALP) which was developed specifically for Pb in soils (Drexler and Brattin, 2007) . The PBET, IVG, and RIVM methods use extraction media that closely mimic the chemical environment of the human gastrointestinal system i.e. they are physiologically based, whereas the RBALP uses physiologically relevant pH of the stomach but uses a glycine buffer as the extraction medium.
As a result of research carried out by BARGE and other research groups it was clear that the different bioaccessibility tests showed similar trends when used on the same soil samples, but the different operating conditions for each test produced widely ranging bioaccessibility values between the methods (Oomen et al., 2002; Saikat et al., 2007; Van de Wiele et al., 2007; Juhasz et al., 2009a; 2009b) . For example, in a study of five different methods on three test soils (Oomen et al., 2002 )a wide range of bioaccessibility values were found: for As 6-95%, 1-19%, and 10-59%; for Cd 7-92%, 5-92%, and 6-99%; and for Pb 4-91%, 1-56%, and 3-90%. This made comparison of data difficult to carry out in a subjective manner causing regulators and risk assessors some concern (Environment Agency, 2005b; Environment Agency, 2005a; Environment Agency, 2007; Richardson, 2008; Scheckel et al., 2009; Latawiec et al., 2010) . To overcome this problem, BARGE undertook a joint decision to progress the development of a harmonised in vitro bioaccessibility method.
The main criteria for the test were:
i) It should be physiologically based, mimicking the human GI physico-chemical environment in the stomach and small intestine. This should not only help to obtain good agreement with in vivo data but would also enhance public understanding of the test;
ii) It should represent a conservative case;
iii) There should be one set of conditions for all potentially harmful elements (PHE) being studied;
iv) It must be demonstrated that the test is a good analogue of in vivo conditions; and v) The test must be able to produce repeatable and reproducible results within and between testing laboratories.
The chosen method was that previously published by researchers at the Dutch Institute of Public Health, the RIVM (Oomen, 2000; Oomen et al., 2002) , as this was considered to be the most suitable static or batch method available, and therefore more likely to be adopted by testing laboratories. The RIVM methodology has also gained acceptance by regulators in both the Netherlands and Denmark. Modifications were made to the RIVM methodology to ensure adequate conservatism, that the in vitro test was robust and applicable to the different soil types found in a range of different countries.
Method performance and benchmarks
The evaluation of the UBM was undertaken by means of an international inter-laboratory exercise. For the method to be 'fit for purpose' the bioaccessibility would need to pass quantitative tests on how well the test could be validated by an in vivo result and how reliably the test could be carried out (repeatability and reproducibility). A validation study of a simple one compartment bioaccessibility test (not physiologically based) for Pb has recently been carried out (Drexler and Brattin, 2007) (Emami, 2006) . The bioavailability of the administered drug, measured by the fraction of the drug absorbed into the human body (equivalent to the animal testing data for metal uptake from soil) is correlated to the in vitro bioaccessibility measured by a dissolution test (equivalent to the UBM bioaccessibility test for soil). The US Federal Drug Administration has set out guidelines for the acceptability of results (1997) which include:
i) A linear relationship with slope of unity, if possible, is preferred, to show that the in vitro dissolution is representative in vivo absorption;
ii) The relative standard deviation (RSD) for the in vitro measurement of a single sample should be less than 10% (repeatability);
iii) The prediction error of the in vivo absorption from the in vitro dissolution test
should not exceed 15% for each formulation (sample).
This provides a basis for setting up performance criteria for the soil bioaccessibility validation. Pharmaceutical formulations are, however, far more homogeneous and less complex than soil samples and therefore these criteria may be too stringent for soil testing. It is necessary to go to the literature to look at the repeatability of inter-laboratory trials on soil testing. Drexler's soil bioaccessibility inter-laboratory trial (2007) reported a repeatability of 4% and reproducibility of 6% (measured as the percent RSD). There are not many other inter-laboratory studies for bioaccessibility testing available; however, there are instances of laboratory trials on soils where PHEs are extracted using different reagents to determine their solid phase distribution and speciation, which is similar to the UBM bioaccessibility test. In the inter-laboratory trial for the European Community
Bureau of Reference (BCR) sequential extraction test on a lake sediment (Quevauviller, 2002 ) the between-laboratory repeatability for Cd was 15, 13 and 75% RSD for three extraction steps and for Pb 19, 5.4 and 29% RSD (As was not determined). Another interlaboratory trial on soils (Nagourney et al., 2008) ii) The within-laboratory repeatability should be ≤10% RSD
iii) The between-laboratory reproducibility should be ≤ 20% RSD
Materials and methods

Samples under investigation
The materials under investigation included slag materials, soils, river sediments and house dusts containing in vivo data for As, Cd and Pb. A number of the donated soils had previously been studied in bioaccessibility investigations and the resulting data reported in the peer reviewed literature (Rodriguez et al., 1999; Rodriguez et al., 2003; Schroder et al., 2003; Schroder et al., 2004; Basta et al., 2007) . Where information on the source of the material, contaminants and subsequent testing data was not readily available in the literature, it was provided by the donor of the individual samples. In addition to in vivo tested soils as a primary source of contaminated material, the evaluation of the UBM also included the two National Institute of Standards and Technology (NIST) standard reference materials (SRMs), 2710 and 2711, which have been studied by various workers in relation to their bioaccessible contaminant contents (Ellickson et al., 2001; Cave et al., 2003; Schroder et al., 2004) . and a soil (BGS 102), containing naturally elevated As concentrations, prepared by the British Geological Survey (BGS) specifically for the purposes of bioaccessibility testing (Wragg, 2009) . Table 1 summarises the materials studied in the inter-laboratory trial, including the material type, references to published information and the total and relative bioavailable data available.
In vitro bioaccessibility method
The in vitro UBM, was a physiological GI simulation based on the methodology utilized at the RIVM, previously described by Oomen et al (2002) . The procedure was carried out according to the schematic in Figure 1 and has been described in full in other publications . The UBM was carried out at 37C (body temperature), at a final soil:solution ratio of 1:100 (g ml in the original methodology). The increased sodium hydrogen carbonate concentration was employed to compensate for the lower, but still physiologically acceptable, stomach pH used in the method (1.2 compared with 1.5 used by the RIVM method). The reason for reducing the pH to 1.2 was based on preliminary studies where calcareous soils were found to cause difficulties in maintaining a low pH in the stomach phase. Reducing the pH to a lower but still physiologically acceptable value of 1.2 helped to alleviate this practical difficulty.
In summary, 9.0 ml of salival fluid was added by pipette to 0.6 g of test material for both the 'stomach' and the 'stomach & intestine' extractions; the extraction vessels were capped and shaken manually for 30s. To each test aliquot, 13.5 ml of gastric fluid was added and the extraction vessels were capped and placed into an extractor and incubated using end-over-end rotation, at 37 ± 2°C for 1 hour. At the end of 1 hour both the 'stomach' and 'stomach & intestine' extracts were removed from the incubator and the pH of the suspension measured. If the pH of the suspension was measured at 1.2 -1.7, the 'stomach' phase extract was deemed complete and the 'stomach & intestine' extract was taken forward to carry out the intestinal digestion phase. If the pH tolerance was not met and there was sufficient solid material available, the UBM extraction was repeated and the pH was adjusted to between 1.2 -1.7 using up to 1.0 ml of concentrated HCl (37% or 12 N). If the pH criterion was met, the 'stomach' phase extract was centrifuged at 3000 g for 5 minutes and a 1.0 ml aliquot preserved by the accurate addition 9.0 ml of 0.1M HNO 3 . To continue the extraction and carry out the 'stomach & intestine' phase, 27.0 ml of duodenal fluid and 9.0 ml of bile fluid were added by pipette, the samples recapped, manually shaken for 30s and the pH checked to ensure that it was 6.3 ± 0.5. If the pH criterion was not met, the pH was adjusted by the dropwise addition of 37% HCl, 1M or 10M NaOH as required and then replaced in the incubator at 37°C and rotated for a further 4 hours. At the end of the intestinal incubation period, the pH was recorded and the suspensions centrifuged for 5 minutes at 3000 g. An aliquot of the supernatant was collected and preserved in the same manner as the 'stomach' phase extractions. Both extraction phases were stored at 1 -8°C. For both the 'stomach' and 'stomach & intestine' phases of the UBM, all contributing laboratories made a record of any additional HCl or NaOH adjustments made to either phase. Because of the small amount of material available for the inter-laboratory trial, it was not possible for all contributing laboratories to carry out repeat extractions because of pH tolerance failures, and therefore some data was reported that was outside the scope of the required tolerances. Two laboratories also carried out the UBM extractions for the As soils at a lower soil to solution ratio of 1:1000 g ml °C. After cooling the samples were capped tightly and stored at 1 -8 °C prior to analysis.
Full details of the selection criteria for the sample tubes and the digestion procedure have been fully described by Wragg et al. ( 2009) .
Bioaccessibility extract analysis
The bioaccessible As, Cd and Pb content of each extract provided was determined directly by a Varian/Vista AX CCD simultaneous instrument with dedicated Varian SPS-5 Auto-sampler and PC running the latest version of ICP Expert software supplied by the instrument manufacturer, according to the operating conditions previously described (Cave and Wragg, 2002; Wragg, 2005) . Each sample was introduced with 1% caesium chloride (as an ionisation buffer) via a peristaltic pump into a glass concentric slurry nebuliser connected to a cyclonic action spray chamber. Analysis was carried out on ~2.5 ml of the UBM digested 'stomach', 'stomach & intestine' extraction solution. Arsenic, Cd and Pb were determined in the UBM extracts after calibration using a minimum of 5 mixed element standards in a 1% HNO 3 matrix. The 'inductively coupled plasma-optical emission spectrometer (ICP-OES) was calibrated to concentrations up to 100 mg l for Cd and re-calibrated after not more than 125 unknown samples. Two quality control standards, at ~10 and 75% of the calibration range, were analysed after each calibration, after no more than ten unknown solutions during the run and at the end of each run to check for drift. As the bioaccessibility matrix had been diluted to a ratio of 1:10 (g ml -1 ) with 0.1M HNO 3 prior to shipping, and digested in mixed HNO 3 /H 2 O 2 on arrival at the lead laboratory no further matching to the calibration or QC standards was deemed necessary. All reported measurements, as mg l mixed element standards were inserted at regular intervals throughout the analysis run and used to correct for any drift in instrument sensitivity. Indium and rhenium were added to all solutions via a T-piece connection and used as internal standards to correct for any matrix suppression. Multi-element QC standards, containing
As, Cd and Pb, were analysed after no more than every 20 unknown samples. Because of limited sample volume, all of the samples were diluted by a factor of two with 1% HNO 3 prior to analysis.
Quality Control
In order to gain an insight into the within-laboratory repeatability, duplicate UBM extractions of each test material, commonly employed reference materials normally used for their total concentrations, blanks and spikes were requested from each participating laboratory. However, due to time constraints this was not possible for all participating laboratories. The reference material QC samples were either the NIST 2710 or 2711 SRM (or both where possible) and the BGS 102 As bioaccessibility guidance soil (Wragg, 2009 , after sample preservation. The spiking solutions were extracted with no test material present to check the percentage (%) recovery of the extraction method, i.e. that no analyte was adsorbed to the extraction tubes or lost during the extraction procedure.
Statistical data analysis
The analytical performance characteristics of the bioaccessibility measurement (repeatability and reproducibility) were determined in the collaborative study using the procedure described in ISO Standard 5725-2 (ISO). Outlier testing using Grubbs' test (Grubbs, 1950 ) and Cochran's test (Snedecor and Cochran, 1980) were carried out in the R statistical programming language using the outliers package (R Development Core Team, 2007) and the outlier removal rules specified in ISO Standard 5725-2 were applied. Repeatability and reproducibility calculations were carried out in MS Excel™. In addition to the ISO 5725-2 statistical calculations, the in vivo relative bioavailability data is plotted against the relative bioaccessibility data to show the relationship between the in vivo and the in vitro measurements. Linear regression analysis was carried out using Theils method (Theil, 1950; Glaister, 2005) that makes no assumption about the errors on the x and y axes and is robust to outliers. Confidence limits on the regression line were calculated using ten thousand Monte Carlo simulations using the uncertainties on the relative bioaccessible and relative bioavailable data. The procedure was implemented in the MATLAB programming language.
4. Results The mean relative bioaccessibilities and associated relative standard deviations for As, Cd and Pb for each sample in each compartment (along with the additional data for the lower soil to solution ratio for As) are given in Tables 2 and 3 .
Quality Control
Each participating laboratory supplied a minimum of three blank extraction samples from each of the UBM phases, under the standard (1:100 g ml -1
) extraction conditions. For the 'stomach phase' extractions, all data for As was returned at below the limit of quantification (<6.75 mg kg -1 ); however, for Cd, one data point for one laboratory was within 2 times the reporting limit (<0.90 mg kg ). Where ICP-AES values for test sample extractions were returned below the reporting limit or the increased soil to solution ratio of 1:1000 (g ml -1
) was employed, the samples were analysed by ICP-MS because of its increased sensitivity and lower reporting limits. The data from the extraction blanks provides a good indication that the reagents or equipment used in the UBM methodology did not contribute As, Cd or Pb to the sample data.
Six of the seven participating laboratories provided a minimum of two mixed element spike extracts for each phase of the UBM, under the standard (1:100 g ml -1
) extraction conditions, for analysis. One laboratory was unable to provide any spike extracts. Figure   2 , a box and whisker plot, summarises the range of mean percentage As, Cd and Pb spike recovery values in each of the two UBM phases for the participating laboratories. Figure   2 shows that, for the 'stomach' phase of the extraction, the As, Cd and Pb recovery was 105 ± 10 %, and that there was a wider spread in the data for the 'stomach & intestine' (Ellickson et al., 2001; Gron and Andersen, 2003) . This is not observed in the case of elements that form anions in solution and is consistent with previous studies for As (Oomen et al., 2006) . For the extractions carried out at the decreased soil:solution ratio, As spike recoveries of 100 and 99% for the 'stomach' and 'stomach & intestine' phases respectively were returned. Table 4 gives a summary of the mean bioaccessible values for each element in each compartment for the quality control reference soils along with the within-laboratory repeatability and the overall between-laboratory reproducibility expressed as the relative standard deviation. This data cannot be used to check accuracy as there are no certified bioaccessible values, but they serve to give an idea of the uncertainty in the results both within and between laboratories for milled and well homogenised soils. BGS102 data tends to have higher within and between-laboratory variability compared with the two NIST soils. This is probably due to the relatively low concentrations of bioaccessible As, Cd and Pb in this soil. After a dilution of 100 in the extraction stage, and a further dilution of 10 in the preservation stage the As, Cd and Pb concentrations in solution are likely to be at or approaching detection limits for the ICP-AES instrument used for the analysis of the extracts. For NIST 2710 and NIST 2711, the bioaccessible concentrations of As, Cd and Pb are significantly higher than BGS 102 so variability from being close to detection limits should not be a problem. The variability of results for the NIST soils is inconsistent from being very good (~3% RSD for Cd and Pb and in NIST 2711 in the stomach phase) to poor (94.6% in NIST 2711 for Pb in the stomach phase). Some of the reasons for these differences are discussed in more detail in sections 4.5 to 4.7 but this exercise suggests the variability is method related and not down to sample heterogeneity.
Total element data
The total As, Cd and Pb concentrations in the test samples were obtained from previously published data using USEPA method 3050 (Schroder et al., 2003; Schroder et al., 2004; Basta et al., 2007) given in Table 1 . However, the BGS laboratories undertook trial digestions of the As samples, which when subjected to a mixed acid digestion (HF, HNO 3 and HClO 4 ) explosive ejections of sample and reagents from the reaction tube were observed. This indicated that the mixed acid digest employed was not suitable for these samples but served to illustrate the unusual geochemistry of these materials, thought to be due to the presence of high concentrations of elemental sulphur.
pH tolerances
The UBM protocol (Figure 1 ) requires that the pH of the individual extracts are checked at the end of the 'stomach' and 'stomach & intestine' phases and the start of the 'stomach & intestine' extraction phase to ensure that acceptable pH values are achieved. Figure 3 and 4 summarise the distribution of the pH data obtained for the end of the 'stomach' phase of the UBM, as a box and whisker plot. Figure 3 shows that the end 'stomach' phase pH tolerance criteria (1.2 to 1.7) for the As soils was met by the contributing laboratories for the majority of the test samples. However, for samples As 6 and 7 a wide range of pH values were observed, ~1.2 to 4.0 and 4.7 respectively. Outliers (denoted as solid black crosses), outside of the pH tolerance were observed for sample As 8 (~pH 2.75 and 3.5), similarly for sample As 9 (pH 2.25) in addition to the maximum value for 
Validation and reliability of the test
The relative bioavailability data obtained from the in vivo studies for the three elements have been obtained by taking the ratio of the amount absorbed from the soil to the amount absorbed from a completely soluble salt of the element. In order to make a meaningful comparison the absolute bioaccessibility as measured by the UBM in vitro test (amount of element extracted from the soil expressed as a percentage of the total element in the soil) was converted to a relative bioaccessibility by dividing the absolute bioaccessibility of the contaminant in the soil by the absolute bioaccessibility of the completely soluble salt. The bioaccessibility of the same salts used in the in vivo studies (As in Na-arsenate, Cd in Cdchloride and Pb in Pb-acetate) were measured using the same UBM procedure used for the soils. In the gastric phase, the absolute bioaccessibility values were 99 ± 2% and 98 ± 3% for Pb in Pb-acetate and Cd in Cd-chloride, respectively. For As in Na-arsenate bioaccessibility was 95 ± 3%. This showed that all three elements were either indistinguishable or within 2% of being 100% bioaccessible for the reference compounds in this compartment. In contrast, in the intestinal phase Pb and Cd had reduced absolute bioaccessibility giving values of 66 ± 3% and 68 ± 3% respectively; however, the As bioaccessibility remained high at 92 ± 4% . The reasons for this are related to the solubility and stability of Cd and Pb in the higher pH solutions as discussed earlier (Ellickson et al., 2001; Gron and Andersen, 2003) . Table 5 gives the values of the assessment criteria (defined at the end of section 2) for each element and each of the simulated GI compartments. The grey highlighted values indicate where the required benchmark value was achieved. Table 5 shows that correlation between in vitro and in vivo data is strong for both compartments, but the slope of the lines are low. Figure 5 show there are some very large uncertainty bars for some samples on both the bioavailable and bioaccessible data. Table   5 and Figures 5(a) , 5(b), 6(a) and 6(b) show that although the within-laboratory repeatability meets the benchmark criteria, the between-laboratory data for both compartments does not. Figure 3 shows that samples As 6 and As 7 deviated significantly from the target pH range compared with the other samples which may have caused poor reproducibility. Figure 5(a) , however, does not show that these samples have higher bioaccessibility uncertainties. Leaving sample As 6 and As 7 out of the calculations for benchmark data for Table 5 did not have any significant effect on the assessment criteria and the data for these two points were therefore retained. In a previous study (Basta et al., 2007) using soils As 1 to As 10 (Table 1) to test a different in vitro bioaccessibility method (the IVG method) the soils As 1 to As 4 are identified as being contaminated with a calcine waste material and samples As 6 to As 10 oxidized waste material (slag) generated from the roasting and/or smelting of arsenopyrite ore. Examination of Figure 5 (a and b) and Table 2 clearly shows that the slag samples, that have the lower total As and higher bioaccessibilities have much poorer reproducibility (high average standard deviation ~12% relative bioaccessibility) compared with the calcine samples (average standard deviation ~0.8% bioaccessibility) suggesting that this is caused by the geochemistry of these samples. Additional geochemical data on these samples (Rodriguez et al., 2003) shows that the calciner samples have relatively acid soil pH (2.6 -3.1) and low Ca concentrations (11.7-18 g kg ). The samples with the highest Ca concentrations test. Additional extractions at the lower soil to solution ratio (1:1000 g ml-1) were carried out on nine of the original samples (the two Aberjona river samples were not extracted at this lower soil to solution ratio due to lack of material). At the lower ratio there was much improved agreement with relative bioavailability.. The r-square values in Table 5 for this ratio indicate a strong correlation with relative bioavailable As, with the slopes of the lines meeting the benchmark criteria. 
Arsenic
Cadmium
For Cd there are comparative data (Schroder et al., 2003) Cd in the stomach compartment but the slope of the line is 0.63 which does not meet the benchmark criteria although this value is in agreement with the slope of the bioaccessibility vs relative bioavailability plot (0.60) using the OSU-IVG method (Schroder et al., 2003) . Figure 5 shows the error bars on the on the relative bioaccessibility values to be less than the relative bioavailability error bars. Table 5 and probably related to the higher pH in this compartment. Cadmium solubility decreases at high pH (Cotton et al., 1999) , the spike recovery (Figure 2) shows that Cd is lost to precipitation at pH 6.3 and complexation by pepsin in the gastro-intestinal compartment (Ellickson et al., 2001; Gron and Andersen, 2003) , and similarly Cd extracted from the soil -at pH 1.2 will undergo the same processes in the 'stomach & intestine' phase. In addition, the soil also provides a sink for sorption at the higher pH conditions which is dependent on individual soil properties. These include the amount of organic matter, clays and Al and Fe oxides present in the soil. All of these can act as sites for specific adsorption at neutral to alkaline pH (Cave et al., 2011) . All of these effects result in a lower slope and poorer reproducibility. Table 5 shows that the slope of the line for the 'stomach' compartment is only just below the benchmark criteria (0.78 compared with a target of 0.8) and the correlation with bioavailable Pb is within the criterion. Examination of Figure 5 (g) and 5(h) and Table 3 shows two groupings in the data, a set of 6 samples with relative bioaccessibilities of 10% or less and a set of 6 samples with relative bioaccessibilities 40% or greater. The former group of 6 samples are those that were only available to one laboratory and only have very low relative bioaccessibilities compared with their relative bioavailabilities. Figure 4 shows that pH at the end of the 'stomach' phase was much higher than specified in the procedure and this may account for the low bioaccessibility values in these samples. This hypothesis is also supported by comparison of the absolute bioaccessibility values from this study with the absolute bioaccessibility values obtained for these six soils using the IVG method (Schroder et al., 2004) Table 5 show that the within-laboratory repeatabilities for the stomach compartments are well within the benchmark criteria but the between-laboratory reproducibility is poor. intestine' are likely to be due the same effects described for Cd .
Lead
Discussion
For As, the low inter-laboratory RSDs and the high between-laboratory RSDs suggest that the small differences between the way the test is applied to these soils has a large effect on the results obtained. These soils have a complex physico-chemical composition and contain very high concentrations of As (Table 1) arising from the mining slag which forms a major part of their mass, which appears to contribute to the reproducibility problems observed in the inter-laboratory trial. This can also be seen in the very high uncertainty in the in vivo measurements (Figures 5(a) to 5(d)). Variability in bioaccessible As can be reduced by careful control of in vitro pH which has been shown to greatly affect the measured metal bioaccessibility (Oomen et al., 2002; Yang et al., 2003; Waisberg et al., 2004; Tang et al., 2006; Tang et al., 2007; Tang et al., 2008) .
However, pH cannot be controlled during in vivo dosing trials used to calculate the relative bioavailability of As in soil. Although the higher dilution test (soil to liquid ratio 1:1000 g ml -1
) was only carried out at two laboratories the soils produce results which meet the benchmark criteria. Possible reasons why the higher dilution gives better results are:
i) The higher dilution removes the problem of As oversaturation which may be the cause of the low slope and poorer reproducibility at low dilution;
ii) At the higher dilution matrix effects (dissolution of concomitant chemical species from the sample, which adversely affect the chemical analysis) from the mine waste material are reduced.
The drawback with using the 1:1000 g ml -1
soil to liquid ratio is that the small amount of sample may cause reproducibility problems if the test soil is inhomogeneous and, if soils
with lower contamination concentrations are tested, the higher dilution may bring the concentrations of the analyte near to or below the method detection limit.
In practical terms, contaminated materials that are relevant to human exposure scenarios where bioaccessibility measurements will have a significant effect on the risk assessment are soils with contaminants close to human health guideline values and not very highly contaminated mine wastes and slags similar to those assessed in this study. When considering these soils, concentration of As will be far lower and the matrix effects much reduced and the problems encountered here are likely to be much reduced. However, it is recognised that mine waste contaminated soils are important in human health risk assessments and that in these cases it may be more appropriate to use the 1:1000 g ml -1
soil to liquid ratio.
For Cd, the method meets all but the slope criteria for the specified benchmarks for the 'stomach' phase (Table 5 ). The low slope and poor repeatability/reproducibility observed in the 'stomach & intestine' phase suggests that the Cd is precipitated out of solution at high pH causing the poor performance.
The Pb data in the 'stomach' compartment for the samples extracted by all the laboratories shows reasonable agreement with the in vivo data but all of these soils have high relative bioavailable values (>50%). The relative bioaccessibility data from the samples with lower relative bioavailabilities is questionable because of the 'stomach' phase tolerances not being met on these samples. Table 5 shows Pb in the 'stomach' phase fits the rsquare and within-laboratory RSD criteria, and is only just outside the slope criteria (0.78, should be ≥0.8) and the between-laboratory RSD criteria (22.78, should be ≤20). For the 'stomach & intestine' phase none of the criteria are met which, like Cd, suggests that precipitation at high pH causes the poor performance.
This study suggests that pH control is a critical factor for obtaining between-laboratory reproducibility. Using tighter pH tolerance on the stomach phase (1.20 ±0.05), Caboche (2009) . Although not a true reproducibility study, the same authors demonstrated between operator repeatabilities for the 'stomach' and the 'stomach & intestine' compartments of 3.4% and 15.2% RSD for Cd and 11.0% and 6.5%
RSD for Pb using the same subset of soils. Without tighter pH control (stomach pH 1.2-1.4), a study of urban soils contaminated from Pb, Zn smelters (Roussel et al.2010) showed repeatabilities for the UBM method for the 'stomach' and the 'stomach & intestine' compartments of 6.3% and 13.8% RSD for Cd and 12.0% and 17.4 % RSD for Pb for the NIST 2710 standard reference material (n=25). Whilst these studies are not directly comparable, there is some evidence that the studies (Caboche, 2009; Pelfrene et al., 2011) with tighter controls on the stomach pH have better repeatabilities than the study )with wider pH limits (< 10 % compared with 6-17% RSD) thus supporting the findings of this study. The between operator study (Pelfrene et al., 2011), although not strictly comparable to a between-laboratory comparison, shows RSD values <20%, again suggesting that the benchmark criteria of <20% RSD should be obtainable with careful control on the method.
The overall purpose of a bioaccessibility test is to provide information for risk assessors on the amount of PHE will be taken into the body via the ingestion route. A validation study comparing in vitro and in vivo data is, in effect, calibrating the bioaccessibility against bioavailability data so that the more easily obtained bioaccessibility values can be used to predict bioavailability. There are a number of uncertainties in relating a bioaccessible value to the amount of PHE absorbed by a human subject. If we assume the swine gastrointestinal model is a good surrogate for humans (Miller and Ullrey, 1987; Moughan et al., 1992) and that there is a linear relationship between bioaccessibility and bioavailability (Schroder et al., 2003; Schroder et al., 2004; Drexler and Brattin, 2007; Juhasz et al., 2007a) then the data from this and similar studies can be used to provide information on the reliability of the data provided to the risk assessor. A simulation was set up using relative bioavailability data on a set of theoretical soils covering the range of 1 to 90% (1, 5, 25, 50, 75 and 90%) with theoretical relative bioaccessibility data on the same soil samples. The simulation used a linear model with slope of unity and intercept of zero where bioavailability is to be predicted from bioaccessibility. The uncertainties are normally distributed on both parameters ranging from 5% to 20% RSD. A Monte Carlo simulation was set up to estimate the uncertainties on the predicted bioavailability. The linear models for the slope and intercept were created using Theils method (Theil, 1950; Glaister, 2005) increases again but it is still possible to distinguish between 5%, 25% and 75% predicted bioavailability. In this study a reproducibility target of 20% has been set; however, Figure   6 shows that the majority of within-laboratory RSD (method repeatability) are better than 10% and therefore with more careful specification of the test (particularly pH control) it should be possible to approach 10% RSD reproducibility. This simulation clearly shows that 20% reproducibility is the maximum tolerable in order to provide useful data for risk assessment.
The simulation also requires that the in vivo bioavailability data should also be better than 20% RSD which may be more difficult to control. Figure 5 shows that the uncertainties on the bioavailability data are in many cases much higher than the bioaccessibility values and therefore improved in vivo data is also required to provide robust validation. The uncertainty simulation clearly shows that improvements in the reproducibility of both the in-vivo and in-vitro measurements are required to give risk assessors more confidence in the use of bioaccessibility data.
Conclusion
In terms of meeting the five main criteria for the bioaccessibility test (listed in section 1), the UBM is physiologically based with one set of extraction reagents used for the three elements considered in this study. The As bioaccessibility measurements, however, required a lower solid to liquid ratio than for Cd and Pb. It is envisaged that this will not be necessary for contaminated soils with As concentrations that are more relevant to human exposure scenarios. The correlations between the in vivo data and the in vitro data suggest that the UBM is a good analogue of in vivo conditions although there is a need to improve the repeatability and reproducibility of the method before this can be clearly demonstrated. The test uses fasted conditions (low stomach pH with no food present) and is therefore likely to give conservative (high bioaccessible values) results, which has been confirmed by an independent study (Caboche, 2009 ) using a comparison against an invivo swine model.. The UBM method does, however, agree well with the IVG in vitro test for As and Cd in the stomach compartments where data for the same soils are available. The IVG method has been validated against swine data for As, Cd and Pb (Schroder et al., 2003; Schroder et al., 2004; Basta et al., 2007) .
This study and others Caboche, 2009; Pelfrene et al., 2011 )that use the UBM have highlighted a number of specific aspects of the UBM test that need to be addressed. There needs to be a review of the practical procedures used in the in vitro test to improve the between-laboratory repeatability. Previous studies have shown the importance of pH of the 'stomach' compartment on the final bioaccessibility result (Oomen et al., 2002) . It is possible that the pH tolerance for the UBM is too wide. This is probably one of the main sources of between-laboratory variability in this study.
For As, it appears that the method will meet the benchmark criteria for both 'stomach'
and 'stomach & intestine' compartments if soils with lower As concentrations (tens to hundreds of mg kg -1
) and with a less complex physico-chemical make up are used. For Cd and Pb it seems possible that the method will work for the 'stomach' phase but not for the 'stomach & intestine' phase; A further follow up study/inter-laboratory trial using test soils with contaminant concentrations more relevant to bioaccessibility testing (e.g. up to 5 times soil guideline values) is required; The As soils provided by Professor Basta have a complex physico-chemical composition, which appears to contribute to the reproducibility problems observed in the inter-laboratory trial; A more rigorous in vivo validation using fasted conditions of the UBM is required; It is not unusual for the first inter-laboratory trial of a new operationally defined procedure for extracting metals from soils to have some initial problems e.g. Quevauviller ( 2002) , which is indeed the case for the UBM method. However, the data indicate that, in general, this in vitro test provides bioaccessibility data which is comparable data to in vivo bioavailability data. The study has highlighted areas of the test which require further refinement but it is our view that with further development this procedure provides a basis for a standardised bioaccessibility test for PHEs in soils. n/a n/a n/a n/a Calcine Soils (Rodriguez et al., 1999; Basta et al., 2007) As 2 17500 4.07 n/a n/a n/a n/a As above
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Nick Basta Pb-Cd studies samples 5 and 4, Jasper Yard soil (Schroder et al., 2003; NBR-256-04 n/a n/a 29.9 10.4 11700 40
Nick Basta Pb-Cd studies samples 12 and 6, Murray Slag (Schroder et al., 2003; NBR-261-04 n/a n/a 43 29.9 8530 14 Nick Basta Pb-Cd studies samples 2 and 2, Butte NPL (Schroder et al., 2003; NBR-267-04 n/a n/a 23.8 56.8 3200 51
Nick Basta Pb-Cd studies samples 13 and 7, Murray Soil (Schroder et al., 2003; NBPb 11 n/a n/a n/a n/a 8170 14 Nick Basta Pb study sample 11, Midvale Slag Soil (2007) NBPb 9 n/a n/a n/a n/a 10600 20 Nick Basta Pb study sample 9, Leadville Slag Soil (2007) B & V 1A n/a n/a n/a n/a 1650 102 Composite Soil B & V 1B n/a n/a n/a n/a 1630 75 Composite Soil B & V 2 TM1 n/a n/a n/a n/a 2280 52 House Dust B & V 2 TM2 n/a n/a n/a n/a 2310 97 Composite Soil DNR5 1 n/a n/a n/a n/a 2830 99 0.5 % Phosphate-treated soil DNR5 2 n/a n/a n/a n/a 4230 76 1 % Phosphate-treated Soil MSE2 n/a n/a n/a n/a 2020 82 Soil for all samples). Where "st" is the stomach compartment and "st+int" is the stomach followed by intestinal compartment. Figure 7 Effect of increasing uncertainty in the bioaccessibility and bioavailability calibration data on the predicted bioavailability. Y axis data have had small shift introduced to so that overlap of error bars can be clearly viewed.
